SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
1 - 8 . (canceled)
9 . A method of treating a disease associated with a neurological disorder, said method comprising:
administering an aminopyridine on a dosing regimen to obtain an in vivo C max :C τ ratio of 1.0 to 3.5 and a C avSS of about 15 ng/ml to about 35 ng/ml.
10 . The method of claim 9 wherein said C max :C τ ratio is about 1.5 to about 3.0.
11 . The method of claim 9 wherein said C max :C τ ratio is about 2.0 to about 3.0.
12 . The method of claim 9 wherein said neurological disorder comprises a spinal cord injury, Alzheimer's disease, multiple sclerosis, or amyotrophic lateral sclerosis.
13 . The method of claim 9 wherein said neurological disorder comprises a spinal cord injury.
14 . The method of claim 9 wherein said neurological disorder comprises multiple sclerosis.
15 . The method of claim 9 wherein said dosing regimen is comprised of administering a tablet twice daily.
16 . The method of claim 15 wherein said twice daily administration comprises every twelve hours.
17 . The method of claim 9 wherein said aminopyridine comprises 4-aminopyridine.
18 - 23 . (canceled)